Abstracts from the ISSAID 2021 Periodic Congress

Table 1 (abstract P34). Treatment modalities and outcomes in patient with DADA2

Treatment	Clinical symptoms			Laboratory tests
Treatment	Vasculitis	Hepato-splenomegaly	Fever	Hb, g/l	PLT, 10⁹/l	WBC, cells/μl	NEU, cells/μl	LYM, cells/μl	CRP, mg/l
Before treatment	+++	+++	+++	59	n/a	n/a	n/a	n/a	n/a
Steroids, 0,1-30 mg/kg	+	-	+/-	133	109	3740	2403	760	16,4
Etanercept, 0,8 mg/kg	-	-	-	52	49	610	200	270	4,62
Etanercept 0,8 mg/kg + steroids 1 mg/kg	-	-	-	144	62	3898	2447	535	1,6
Ruxolitinib, 10 mg/m²	-	-	-	154	91	5890	4317	967	1,4

Hb – hemoglobin, PLT – platelet count, WBC – white blood cell count, NEU – neutrophil count, LYM – lymphocyte count, CRP – C-reactive protein. Laboratory test results show median values for the observation time

ISSN: 1546-0096